期刊文献+

喹硫平合并帕罗西汀治疗强迫症临床研究 被引量:1

A Clinical Study of the Efficacy of Quetiapine Combined with Paroxetine in the Treatment of Obsession
原文传递
导出
摘要 目的:探讨喹硫平合并帕罗西汀治疗强迫症的临床疗效和安全性。方法:将47例强迫症患者随机分为帕罗西汀组,喹硫平合并帕罗西汀组,随访8周。采用Yale-Brown强迫症量表(Y-Bocs),汉密尔顿焦虑量表(HAMA)和副反应量表(TESS)评定疗效和不良反应。结果:基线时两组间Y-BOCSHAMA评分相似。随访第8周时喹硫平合并帕罗西汀组Y-BOCS评分(12.4±4.7)低于帕罗西汀组(16.1±3.9,t=2.576,P=0.037),HAMA评分(6.9±3.8)也低于帕罗西汀组(10.1±3.6,t=2.236,P=0.017)。结论:喹硫平合并帕罗西汀用于强迫症的治疗有明确的疗效和安全性。 Objective:To evaluate the clinical efficiency and safety of quetiapine combined with paroxetine in treating obsession.Methods:47 patients with obsession were randomly divided into paroxetine group and quetiapine with paroxetine group,and then follow up for 8 weeks.Yale-Brown Obsessive-compulsive disorder scale(Y-BOCS),Hamilton anxiety scale(HAMA)and treatment emergent symptom scale(TESS)were used to evaluate the efficiency and adverse effects.Results:The scores of Y-BOCS and HAMA at the base time were Similarly.Yet the Y-BOCS score of the quetiapine with paroxetine group(12.4±4.7)was lower than it of the paroxetine group(16.1 ±3.9,t=2.576,P=0.03).The HAMA score of the quetiapine with paroxetine group(6.9±3.8)was lower than the it of the paroxetine group(10.1±3.6,t=2.236,P=0.017).Conclusion:Quetiapine combined with paroxetine have exacta efficiency and safety in treating Obsession.
出处 《慢性病学杂志》 2010年第4期299-300,共2页 Chronic Pathematology Journal
关键词 抗精神病药/治疗应用 帕罗西汀/治疗应用 药物疗法 联合 强迫性人格障碍/药物疗法 人类 Antipsychotic Agents/therapeutic use Paroxetine/therapeutic use Drug Therapy Combination Compulsive Personality Disorder/drug therapy Humans
作者简介 张明松(1961-),男,河南平舆县人,主治医师。研究方向:精神分裂症的诊断与治疗。
  • 相关文献

参考文献9

二级参考文献38

  • 1赵业华.奎硫平治疗首发精神分裂症86例临床观察[J].临床精神医学杂志,2004,14(4):230-230. 被引量:7
  • 2王登峰.自我和谐量表的编制[J].中国临床心理学杂志,1994,2(1):19-22. 被引量:549
  • 3梁海翔,李翔,任丽娜.奎硫平与氯丙嗪辅助碳酸锂治疗躁狂发作疗效分析[J].临床精神医学杂志,2005,15(3):173-174. 被引量:15
  • 4刘俊丽,刘云波,冯正直,杨国愉,夏本立,钟铁军,汪涛,廖雅琴,秦爱粉,王江澜,张艳,汪凤.12486名军人SCL-90测试结果分析[J].中国健康心理学杂志,2005,13(6):423-427. 被引量:96
  • 5Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiat, 2006, 51 ( 8 Suppl 2) : 9 -91.
  • 6Geller DA. Obsessive - compulsive and spectrum disorders in children and adolescents. Psychiatr Clin N Am, 2006, 29 (2) :353 -370.
  • 7Grados MA, Riddle MA. Pharmacological treatment of childhood obsessive- compulsive disorder: from theory to practice. J Clin Child Psyehol, 2001,30( 1 ) : 110 - 113.
  • 8Denys D, Fineberg N, Carey PD, et al. Quetiapine addition in obsessive- compulsive disorder: is treatment outcome affected by type and dose of serotonin reuptake inhibitors? Biol Psychiat, 2007,61 ( 3 ) ;412 -414.
  • 9Denys D, Klompmakers AA, Westenberg HG. Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine. Psychopharmacol,2004,176 ( 2 ) : 195 - 203.
  • 10Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol, 2007, 100( 1 ) :4 - 22.

共引文献54

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部